Aurobindo forms JV with Russian firm for generic products

Image
Press Trust of India Hyderabad
Last Updated : Jan 21 2013 | 12:12 AM IST

Aurobindo Pharma today said it has formed an equal joint venture with Russian healthcare equipment company Ojsc Diod to manufacture and sell drugs in Russia, Belarus and Kazakhstan.

Aurospharma Company, the new JV will set up a plant to make Non Penicillin and Non Cephalosporin Rx generics and other drugs that are categorised as Over-the-Counter (OTC) products in Russia, the company said in a release.

In addition, the JV will source Penicillin, Cephalosporin and few other therapy products manufactured by Aurobindo Pharma to sell in Russia, Belarus and Kazakhstan.

o Associate Vice President Vishnu Sriram said, "The JV format gives us an opportunity to localize our production in Russia. Using the Russian partner’s marketing vision, we will be able to enter the growing and challenging Russian market with greater confidence and expedite our presence in the market."

"Aurobindo will enrich the JV with its successful international experience in manufacturing medicinal substances and drugs – the so-called generics."

The plant to be built in Russia will focus on production of socially significant medicinal drugs.

The plant with the GMP standards will be constructed in the Podolsk District (Moscow region) and is expected that the construction will be completed and the plant will attain its rated capacity closer to the end of 2013.

"The establishment of the JV should allow us to become an important player at the Russian pharmaceutical market within the target period," Vladimir Tikhonov, Diod CEO, said.

Aurobindo shares closed 3.31% higher at Rs 137.25 on the Bombay Stock Exchange today.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 07 2011 | 5:46 PM IST

Next Story